• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Ekso Bionics Holdings Inc.

    5/12/26 8:30:02 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials
    Get the next $EKSO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    ChronoScale Corporation

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)




    170924104

    (CUSIP Number)
    Wesley Cummins
    2811 Turtle Creek Blvd., Suite 2100,
    Dallas, TX, 75219
    (214) 556-2465


    Steven E. Siesser, Esq.
    Lowenstein Sandler LLP, 1251 Avenue of the Americas
    New York, NY, 10020
    (212) 204-8688

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/05/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    170924104


    1 Name of reporting person

    Applied Digital Corporation
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    139,528,227.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    139,528,227.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    139,528,227.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    97.5 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    See Item 5 for additional information.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.001 par value per share
    (b)Name of Issuer:

    ChronoScale Corporation
    (c)Address of Issuer's Principal Executive Offices:

    3811 Turtle Creek Blvd. Suite 2100, Dallas, TEXAS , 75219.
    Item 2.Identity and Background
    (a)
    This Schedule 13D is filed by Applied Digital Corporation, a Delaware corporation (the "Reporting Person"). APLD Intermediate HoldCo LLC, a Delaware limited liability company ("APLD Intermediate") is a wholly owned subsidiary of the Reporting Person. APLD ChronoScale HoldCo LLC, a Delaware limited liability company ("APLD ChronoScale") is a wholly-owned subsidiary of APLD Intermediate. Set forth on Appendix A are the names of the members of the board of directors and executive officers of the Reporting Person and certain other persons associated with the Reporting Person (collectively, the "Covered Persons"). Appendix A is incorporated by reference herein as Exhibit 1. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
    (b)
    The business address for the Reporting Person and the Covered Persons is 3811 Turtle Creek Blvd., Suite 2100, Dallas, TX, 75219.
    (c)
    The principal business of the Reporting Person is the design, development and operation of digital infrastructure solutions for the high-performance computing, artificial intelligence and blockchain industries. The principal occupation of each of the Covered Persons is set forth on Appendix A.
    (d)
    During the last five years, neither the Reporting Person nor the Covered Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, neither the Reporting Person nor the Covered Persons were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction or was subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    The Reporting Person is a Nevada corporation. Each of the Covered Persons is a citizen of the United States.
    Item 3.Source and Amount of Funds or Other Consideration
     
    The securities of ChronoScale Corporation (f/k/a Ekso Bionics Holdings, Inc.) (the "Issuer") reported herein were acquired by the Reporting Person through (i) the exchange by APLD ChronoScale, an indirect wholly owned subsidiary of the Reporting Person, of 1,200 shares, constituting all of the issued and outstanding equity of Applied Digital Cloud Corporation ("Cloud") for 138,216,820 shares of common stock, par value $0.001 per share (the "Common Stock") of the Issuer (the "Exchanged Shares"), at the closing (the "Closing") of the business combination (the "Business Combination") on May 5, 2026 (the "Event Date") pursuant to the Contribution and Exchange Agreement, dated February 15, 2026, by and among the Issuer, APLD ChronoScale, APLD Intermediate and Cloud (the "Contribution and Exchange Agreement"), and (ii) the purchase by the Reporting Person, for cash, of 1,311,407 shares of Common Stock (the "Private Placement Shares") in a private placement (the "Private Placement" and, together with the Business Combination, the "Transactions") completed immediately prior to the Closing pursuant to the Securities Purchase Agreement, dated May 1, 2026, by and between the Issuer and the Reporting Person (the "Securities Purchase Agreement"). The purchase price for the Private Placement Shares was $12.01 per share, the closing price of the Common Stock on April 30, 2026, the date immediately preceding the date of execution of the Securities Purchase Agreement, for an aggregate purchase price of approximately $15.75 million, which was funded from the Reporting Person's working capital.
    Item 4.Purpose of Transaction
     
    The Reporting Person acquired the securities of the Issuer in connection with (i) the Business Combination contemplated by the Contribution and Exchange Agreement, pursuant to which Cloud became a wholly owned subsidiary of the Issuer and Ekso Bionics Holdings, Inc. changed its name to ChronoScale Corporation, and (ii) the Private Placement contemplated by the Securities Purchase Agreement. As a result of the Transactions, the Reporting Person is deemed to beneficially own a majority of the voting power of all outstanding shares of the Issuer's Common Stock and the Issuer is a "controlled company" within the meaning of Nasdaq's corporate governance standards. In connection with, and effective upon, the Closing, the Issuer and APLD ChronoScale entered into an Investor Rights Agreement (the "Investor Rights Agreement") that, among other things, provides the Reporting Person and its affiliates, with board designation rights, certain consent rights, preemptive rights and registration rights with respect to the Exchanged Shares and the Private Placement Shares. The Reporting Person acquired beneficial ownership of the securities reported herein of the Issuer for investment purposes. Pursuant to the Investor Rights Agreement, the APLD Designator (as defined therein) has the right to designate four (4) of the seven (7) directors on the Issuer's board of directors, including the Chairman (each such director, an "APLD Designee"). The initial APLD Designees are Wesley Cummins (Chairman), Ella Benson, Douglas Miller and Richard Nottenburg. At the Closing, the Issuer and the Reporting Person also entered into a Management Advisory and Corporate Services Agreement (the "Services Agreement"), pursuant to which the Reporting Person agreed to provide management advisory services and certain corporate services to the Issuer in exchange for the fees described therein. For the avoidance of doubt, the Services Agreement does not relate to the acquisition, disposition, voting or transfer of Issuer securities. Although the Reporting Person and the Covered Persons are considering, or may consider in the future, plans or proposals with respect to their investment in the Issuer that could relate or would result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D, except as set forth in this Schedule 13D, neither the Reporting Person nor the Covered Persons have any present plan or proposal which would relate to or result in any such matters. The Reporting Person and Covered Persons have had discussions with management of the Issuer, other members of the Board, other representatives of the Issuer and other investors regarding the Issuer, including but not limited to its operations, strategy, management, capital structure, their investment in the Issuer and strategic alternatives that may be available to the Issuer. Such discussions may concern ideas, plans or proposals that, if effected, may result in one or more of the events described in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Person and the Covered Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including the Issuer's financial position and strategic direction, price levels of the securities of the Issuer, other investment opportunities available to the Reporting Person and the Covered Persons, conditions in the securities market and general economic and industry conditions, the Reporting Person and the Covered Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate, including, without limitation, acquiring additional securities of the Issuer and/or retaining, converting and/or selling all or a portion of the securities of the Issuer held by the Reporting Person or the Covered Persons, if any, in the open market or in privately negotiated transactions, and/or may distribute securities of the Issuer to be acquired or held by the Reporting Person or the Covered Persons to shareholders of the Reporting Person, other entities engaging in communications with other directors and officers of the Issuer, other stockholders of the Issuer or other third parties or taking steps to implement a course of action, including, without limitation, engaging advisors, including legal, financial, regulatory, technical and/or industry advisors, to assist in any review. Such discussions and other actions may relate to various alternative courses of action, including, without limitation, those related to an extraordinary corporate transaction (including, but not limited to a merger, reorganization or liquidation) involving the Issuer or any of its subsidiaries; business combinations involving the Issuer or its subsidiaries; a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; material asset purchases; the formation of joint ventures with the Issuer or its subsidiaries or the entry into other material projects; changes in the present business, operations, strategy, future plans or prospects of the Issuer, financial or governance matters; changes to the board of directors (including composition of the board of directors) or management of the Issuer; acting as a participant in debt financings of the Issuer or its subsidiaries, changes to the capitalization, ownership structure, dividend policy, business or corporate structure or governance documents of the Issuer; de-listing or de-registration of the Issuer's securities; any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D or any action similar to those enumerated above.
    Item 5.Interest in Securities of the Issuer
    (a)
    As of the Event Date and the date of this Schedule 13D (the "Filing Date"), the Reporting Person may be deemed to beneficially own 97.5% of the outstanding shares of the Issuer, or 139,528,227 shares, consisting of 1,311,407 shares held directly and 138,216,820 shares held indirectly through its wholly owned subsidiaries. As of the Event Date and the Filing Date, the Issuer had 143,093,381 shares of Common Stock outstanding, based on information reported by the Issuer in its Current Report on Form 8-K/A filed with the Securities and Exchange Commission (the "SEC") on May 5, 2026.
    (b)
    The information contained on the cover page to this Schedule 13D is incorporated by reference into this Item 5.
    (c)
    Except as set forth in this Schedule 13D, no transactions in the Common Stock have been effected by the Reporting Person or the Covered Persons during the past sixty days prior to (i) the Event Date and (ii) the Filing Date.
    (d)
    None.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    In connection with the transactions described in Item 3 and Item 4, the Reporting Person and the Covered Persons are parties to, or beneficiaries of, the following agreements, as applicable, with the Issuer relating to the Issuer's securities, each of which is incorporated by reference herein: The Contribution and Exchange Agreement by and among the Issuer, APLD Intermediate, APLD ChronoScale and Cloud, pursuant to which APLD ChronoScale received 138,216,820 shares of Common Stock in exchange for all of the outstanding equity of Cloud at Closing. The Investor Rights Agreement which, among other things, provides board designation rights, specified consent rights while the APLD Investors (as defined therein) beneficially own certain thresholds of voting power, preemptive rights and resale registration rights for registrable securities (including the Private Placement Shares). The Securities Purchase Agreement by and between the Issuer and the Reporting Person, pursuant to which the Reporting Person purchased 1,311,407 shares of Common Stock at a price of $12.01 per share for aggregate consideration of approximately $15.75 million. In addition, on April 9, 2026, APLD ChronoScale Management LLC ("APLD Management") granted to certain of the Covered Persons certain profits interests in the form of Management Incentive Plan Units (the "MIP Units") pursuant to the APLD ChronoScale Management LLC Equity Incentive Plan. The MIP Units were fully vested upon grant and are designed to track the appreciation of the equity of the Issuer and are held by each recipient personally, not by the Reporting Person. The MIP Units do not confer on the recipients any present power to dispose of, or to direct the disposition of, any securities of the Issuer as any such sale is subject to the discretionary approval of APLD Management and, if approved, would be effected by such entity, and the recipients do not have a unilateral right to cause a sale within 60 days. In the aggregate, the awards to the recipients represent approximately 5.25% of the Issuer's shares of common stock issued to APLD ChronoScale pursuant to the Contribution and Exchange Agreement. Except as set forth in this Schedule 13D, neither the Reporting Person nor, to its knowledge, any of the Covered Persons are a party to any contract, arrangement, understanding or relationship with respect to any securities of the issuer, including but not limited to transfer or voting of any of the securities, finders' fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1 - Appendix A Exhibit 2 - Contribution and Exchange Agreement, dated February 15, 2026, by and among ChronoScale Corporation (f/k/a Ekso Bionics Holdings, Inc.), APLD ChronoScale HoldCo LLC, APLD Intermediate HoldCo LLC, and Applied Digital Cloud Corporation (incorporated by reference to Exhibit 10.1 to Applied Digital Corporation's Current Report on Form 8-K filed with the SEC on February 17, 2026). Exhibit 3 - Investor Rights Agreement by and between ChronoScale Corporation and APLD ChronoScale Holdco LLC, dated May 5, 2026 (incorporated by reference to Exhibit 10.4 to Applied Digital Corporation's Current Report on Form 8-K/A filed with the SEC on May 5, 2026).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Applied Digital Corporation
     
    Signature:/s/ Saidal Mohmand
    Name/Title:Saidal Mohmand / Chief Financial Officer
    Date:05/12/2026
    Get the next $EKSO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EKSO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EKSO
    SEC Filings

    View All

    Ekso Bionics Holdings Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

    8-K - ChronoScale Corp (0001549084) (Filer)

    6/4/26 4:15:33 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Amendment: Ekso Bionics Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - ChronoScale Corp (0001549084) (Filer)

    5/20/26 5:14:33 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form SCHEDULE 13D filed by Ekso Bionics Holdings Inc.

    SCHEDULE 13D - ChronoScale Corp (0001549084) (Subject)

    5/12/26 8:30:02 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

    DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN) ("ChronoScale" or the "Company"), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer. The appointments strengthen ChronoScale's executive leadership team as the Company expands its AI infrastructure platform and accelerates delivery of large-scale compute solutions for enterprises, hyperscalers, and AI innovators worldwide. "AI infrastructure is entering a new era where performance, efficiency, and execution matter more than ever," said Ce

    6/4/26 8:00:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    ChronoScale Appoints Cenly Chen as Chief Executive Officer to Lead Next Phase of AI Compute Growth

    DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointment of Cenly Chen as Chief Executive Officer and a member of the Company's Board of Directors. Ms. Chen brings more than two decades of experience scaling enterprise infrastructure and high-performance computing platforms in global markets. She most recently served as Chief Growth Officer, Senior Vice President & Managing Director at Super Micro Computer, Inc. (NASDAQ:SMCI), where she led global growth initiatives across AI and enterprise infrastructure markets. "We believe the mar

    5/6/26 8:00:00 AM ET
    $EKSO
    $SMCI
    Industrial Machinery/Components
    Industrials
    Computer Manufacturing
    Technology

    Ekso Bionics Prices $5.852 million Private Placement

    SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the "Company") (NASDAQ:EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and accredited investors for the purchase and sale of an aggregate of 5,852 shares of the Company's Series B Preferred Stock (the "Preferred Stock") and warrants (the "Warrants") to purchase up to an aggregate of 355,960 shares of common stock of the Company in a private placement transaction (the "Private Placement"). The shares of Preferred Stock will have a stated value of $1,000 per share and b

    1/21/26 8:30:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cummins Wes was granted 200,000 shares (SEC Form 4)

    4 - ChronoScale Corp (0001549084) (Issuer)

    5/18/26 6:00:28 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Director Miller Douglas S was granted 200,000 shares (SEC Form 4)

    4 - ChronoScale Corp (0001549084) (Issuer)

    5/18/26 6:00:24 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Director Benson Ella G. was granted 200,000 shares (SEC Form 4)

    4 - ChronoScale Corp (0001549084) (Issuer)

    5/18/26 6:00:27 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asher Daniel bought $191,162 worth of shares (15,540 units at $12.30) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/20/26 4:57:37 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $11,520 worth of shares (1,200 units at $9.60) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/19/26 4:03:47 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $970,069 worth of shares (102,029 units at $9.51) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/17/26 3:42:24 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Leadership Updates

    Live Leadership Updates

    View All

    ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy

    DALLAS, June 04, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN) ("ChronoScale" or the "Company"), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointments of Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer. The appointments strengthen ChronoScale's executive leadership team as the Company expands its AI infrastructure platform and accelerates delivery of large-scale compute solutions for enterprises, hyperscalers, and AI innovators worldwide. "AI infrastructure is entering a new era where performance, efficiency, and execution matter more than ever," said Ce

    6/4/26 8:00:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    ChronoScale Appoints Cenly Chen as Chief Executive Officer to Lead Next Phase of AI Compute Growth

    DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- ChronoScale Corporation (NASDAQ:CHRN), an accelerated compute platform purpose-built to support demanding artificial intelligence workloads, today announced the appointment of Cenly Chen as Chief Executive Officer and a member of the Company's Board of Directors. Ms. Chen brings more than two decades of experience scaling enterprise infrastructure and high-performance computing platforms in global markets. She most recently served as Chief Growth Officer, Senior Vice President & Managing Director at Super Micro Computer, Inc. (NASDAQ:SMCI), where she led global growth initiatives across AI and enterprise infrastructure markets. "We believe the mar

    5/6/26 8:00:00 AM ET
    $EKSO
    $SMCI
    Industrial Machinery/Components
    Industrials
    Computer Manufacturing
    Technology

    Ekso Bionics Accepted into NVIDIA Connect Program

    Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

    5/15/25 7:45:00 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Financials

    Live finance-specific insights

    View All

    Ekso Bionics Reports Second Quarter 2025 Financial Results

    SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into the NVIDIA Connect program, supporting Ekso's new strategic initiative to build a proprietary foundation model for human motion and to help develop and integrate related new artificial intelligence

    7/28/25 4:05:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow

    SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at ww

    7/21/25 4:45:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Ekso Bionics Reports First Quarter 2025 Financial Results

    SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

    5/5/25 4:05:00 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

    SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    11/14/24 3:29:01 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Ekso Bionics Holdings Inc. (Amendment)

    SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    2/11/22 6:17:59 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed

    SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    2/12/21 10:16:25 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials